
Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?
CNN
Pfizer, BioNTech and Moderna are experiencing a post-vaccine hangover on Wall Street this year.
All three stocks surged spectacularly in 2021, thanks largely to their Covid-19 vaccines' success and strong sales. But 2022 hasn't been as kind to them. Shares of Pfizer (PFE) are down about 15%, while its Comirnaty vaccine partner BioNTech (BNTX) has fallen 35%. Moderna (MRNA) has fared even worse, plunging more than 40%.
What gives? Sales of the Covid vaccines aren't the problem. Pfizer has said that it expects revenue from Comirnaty, which it splits equally with BioNTech, to hit $32 billion in 2022 while Moderna has forecast that it could generate nearly $20 billion in revenue from its coronavirus shot this year.

Jeffrey Epstein survivors are slamming the Justice Department’s partial release of the Epstein files that began last Friday, contending that contrary to what is mandated by law, the department’s disclosures so far have been incomplete and improperly redacted — and challenging for the survivors to navigate as they search for information about their own cases.












